The Top 5 Biosimilar Articles for the Week of November 22

Here are the top 5 biosimilar articles for the week of November 22, 2021.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of November 22, 2021.

Number 5: A study from a free market–focused think tank argued for the elimination of market barriers to biosimilars to tap potentially billions of dollars in health care system savings that biosimilars for 2 widely used drugs could provide.

Number 4: Authors of a review discussed barriers to insulin access and potential solutions as the 100-year anniversary of the drug's first use for diabetes gets closer.

Number 3: Progression-free survival (PFS) was improved for patients with epidermal growth factor receptor–mutated nonsquamous non–small cell lung cancer who were treated with PD-1 and antivascularization therapy.

Number 2: A new white paper from Samsung Bioepis and Organon took aim at misconceptions about biosimilars and industry practices that hinder their adoption.

Number 1: A European Medicines Agency (EMA) pilot program to advise manufacturers how to minimize or avoid clinical trial requirements was based on wrong assumptions about the biosimilar development process.

To read all of these articles and more, visit centerforbiosimilars.com.